Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 May;44(5):682-6.
doi: 10.1136/gut.44.5.682.

Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

E P Bouras  1 , M Camilleri, D D Burton, S McKinzie
Affiliations
Clinical Trial

Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

E P Bouras et al. Gut. 1999 May.

Abstract

Background: Prucalopride (R093877) is a selective and specific 5HT4 agonist, the first of a new chemical class of benzofurans, with gastrointestinal prokinetic activities in vitro.

Aims: To evaluate the effects of prucalopride on gastrointestinal and colonic transit.

Methods: A validated scintigraphic technique was used to measure gastrointestinal and colonic transit over 48 hours in 50 healthy volunteers. For seven days, each subject received a daily dose of 0. 5, 1, 2, or 4 mg prucalopride, or placebo in a double blind, randomised fashion. The transit test was performed over the last 48 hours.

Results: There were significant accelerations of overall colonic transit at 4, 8, 24, and 48 hours (p<0.05) and proximal colonic emptying t1/2 (p<0.05). The 0.5, 2, and 4 mg doses of prucalopride were almost equally effective and accelerated colonic transit compared with placebo. Prucalopride did not significantly alter gastric emptying (p>0.5) or small bowel transit (overall p=0. 12). The medication appeared to be well tolerated during the seven day treatment of healthy subjects.

Conclusion: Prucalopride accelerates colonic transit, partly by stimulating proximal colonic emptying, but does not alter gastric or small bowel transit in healthy human subjects. Prucalopride deserves further study in patients with constipation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Experimental procedure.
Figure 2
Figure 2
Effect of prucalopride on overall colonic transit (geometric centre) at 4 (A), 8 (B), 24 (C), and 48 (D) hours. ANOVA shows significant overall drug effect (at least one dose at each time point; *p<0.05) at all times. Dunnett's test shows significant effects of the 0.5 and 2.0 mg doses versus placebo.
Figure 3
Figure 3
Effect of prucalopride on proximal colonic emptying half time; the drug has an overall significant effect on t1/2; the t1/2 values observed with the 0.5 and 2.0 mg doses are significantly lower than those with placebo (Dunnett's test, *p<0.05).
See this image and copyright information in PMC

References

    1. Gastroenterology. 1982 Sep;83(3):529-34 - PubMed
    1. Gut. 1998 Apr;42(4):511-6 - PubMed
    1. Gastroenterology. 1987 Feb;92(2):414-20 - PubMed
    1. Gut. 1987 Jan;28(1):13-6 - PubMed
    1. Am J Physiol. 1989 Aug;257(2 Pt 1):G284-90 - PubMed

Publication types